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Innate lymphoid cells (ILCs) play a central role in
the response to infection by secreting cytokines
crucial for immune regulation, tissue homeostasis,
and repair. Although dysregulation of these sys-
tems is central to pathology, the impact of HIV-1
on ILCs remains unknown. We found that human
blood ILCs were severely depleted during acute
viremic HIV-1 infection and that ILC numbers did
not recover after resolution of peak viremia. ILC
numbers were preserved by antiretroviral therapy
(ART), but only if initiated during acute infection.
Transcriptional profiling during the acute phase re-
vealed upregulation of genes associated with cell
death, temporally linked with a strong IFN acute-
phase response and evidence of gut barrier break-
down. We found no evidence of tissue redistribu-
tion in chronic disease and remaining circulating
ILCs were activated but not apoptotic. These data
provide a potential mechanistic link between acuteHIV-1 infection, lymphoid tissue breakdown, and
persistent immune dysfunction.
INTRODUCTION
Hallmarks of HIV-1 pathology include immunodeficiency,
lymphoid tissue destruction, gut barrier breakdown, and sys-
temic immune activation (Veazey et al., 1998). These features
are only partially reversed by fully suppressive long-term an-
tiretroviral therapy (ART) (Sanchez et al., 2015; Zeng et al.,
2012). The underlying mechanisms remain unclear, presenting
a serious barrier to the development of novel interventions to
improve immune reconstitution in HIV-1-infected individuals.
Recent studies suggest that the rapid depletion of interleukin
17 (IL-17)- and IL-22-producing CD4+ T cells within gut-asso-
ciated lymphocyte tissue (GALT) during acute infection
(Schuetz et al., 2014) leads to gut epithelial breakdown,
because IL-17 and IL-22 are the key cytokines in mucosal ho-
meostasis. In fact, the most rapid and prolific producers of
IL-17 and IL-22 in tissue are innate lymphoid cells (ILCs)
rather than conventional Th17 and Th22 cells (Cella et al.,
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happens to this important immune subset after HIV-1
infection?
ILCs are not antigen specific and lack rearranged B and T cell
receptors. ILCs are grouped into ILC1, ILC2, and ILC3, which
share functional characteristics with Th1, Th2, and Th17 cells,
respectively (Spits et al., 2013). ILCs respond rapidly to damage,
prior to B and T cell expansion, and are therefore crucial for tis-
sue homeostasis and repair during acute and chronic disease
(McKenzie et al., 2014). In particular, ILCs are important in
mucosal barrier maintenance through tissue repair, wound heal-
ing, and regulation of the immune response to commensals (Tait
Wojno and Artis, 2012). As a result, ILCs are emerging as key
players in many infectious and non-infectious diseases, where
they can aid or impair proper immune response. Illustratively,
group 2 ILCs (ILC2s) accumulate in the lung after influenza infec-
tion and restore epithelial integrity (Monticelli et al., 2011), and
loss of gut ILC3s precipitates inflammatory bowel conditions
through the IL-22 axis (Sonnenberg et al., 2012; Tait Wojno
and Artis, 2012). In contrast, untreatedmultiple sclerosis, allergic
asthma, and psoriasis are associated with expansions of ILCs in
peripheral blood that might drive pathology (Bartemes et al.,
2014; Perry et al., 2012; Teunissen et al., 2014).
The impact of HIV-1 on ILC populations in circulation and at
mucosal barrier sites remains unclear. Given the central role of
ILCs in gut epithelial integrity, immune regulation, and other sys-
tems dysregulated in HIV-1 disease, this represents a significant
gap in our understanding of HIV-1 pathology.
In this study, we found that circulating ILCs were depleted
7–14 days after infection, in conjunction with an acute phase im-
mune response. ILC numbers did not recover, in chronic infec-
tion, even with long-term fully suppressive ART. In contrast, we
found that ILC populations were maintained if ART was started
during early acute infection before peak viremia. We show that
remaining ILCs circulating in chronic disease display an activated
phenotype, but no direct evidence of apoptosis or migration to
tissue sites. RNA sequencing of ILCs during early acute infection
implicates apoptosis and cell death during ILC depletion. TheseFigure 1. Identification of Human ILCs from Blood Shows HIV-Specific
(A) Representative conventional flow cytometry plots from an HIV-1-uninfected
phocytes to the ILC1 (orange), ILC2 (red), and ILC3 (blue) populations indicated
CD11c, CD14, CD19, CD34, BDCA2, FcER1, TCR-ab, and TCR-gd antibodies.
(B) tSNE clustering of human PBMCs pre-gated for lymphocytes/singlets/live/C
dimensional space based on phenotype markers CD161, CD117, CD56, CRTH2,
identified clusters with heatmap showing the relative expression intensity for eac
(C) Cytokine production after media or PMA/ionomycin stimulation from blood CD
IL-17A, and IL-22) with tonsil-derived ILC3 shown as NKp44 versus IL-22.
(D) Transcription factor expression within CD4+ Th2 cells (CRTH2 gated), CD4+ Th
for T-bet, GATA-3, and RORgt.
(E) Innate lymphoid cell score based on RNA-seq generated gene expression w
uninfected individuals based on recently published gene transcripts of ILCs (Rob
(F) Absolute ILC counts for HIV-1-uninfected (n = 136), HIV-1-infected with und
detectable viremia (VL > 50) (n = 91).
(G) ILC frequency expressed as percent of CD45+ lymphotyces for HIV-1-uninfec
and HIV-1-infected individuals with detectable viremia (VL > 50) (n = 115). p valu
(H) Grouping of cells gated from lymphs/singlets/live/CD45+/CD3/Lin/CD127+
from 18 HIV-1-uninfected (left) and 21 HIV-1-infected subjects with each distinct
(I) Bar graph showing the mean percentage contribution from each cluster (x axis
with p < 0.02 indicated by asterisk and calculated by t test comparing HIV-1-uninfe
and Sidak-Bonferroni method for multiple comparisons.
See also Figures S1 and S2.gene signatures were diminished by early ART. Together these
data suggest that depletion of circulating ILCs was mediated
by cell death driven by high viral load (VL) during acute HIV-1
infection and associated with markers of acute viral response.
RESULTS
ILCs Are Depleted during Chronic HIV-1 Infection and
Inversely Correlate with Viral Load Setpoint
ILCs are defined as lymphocytes that are negative for B and T cell
lineage markers and conventional natural killer (NK) cell markers
(CD16 and CD94) but positive for CD127 and CD161. Using flow
cytometry of peripheral blood samples from HIV-1-infected and
uninfectedhumandonors, we adopteda traditional gating strategy
and identified three phenotypically distinct ILC populations as
described (Spits et al., 2013): CRTH2CD117CD56CD25/+
(ILC1), CRTH2+CD117/+CD56CD25/+ (ILC2), and CRTH2
CD117+CD56/+CD25/+ (ILC3) (Figures 1A and S1A). To verify
the identity of these three ILC populations, we turned to an unbi-
ased data analysis tool, t-distributed stochastic neighbor embed-
ding (tSNE), which simultaneously analyzes all flow-measured
parameters, rather than sequentially gating. tSNE, like a prin-
cipal-component analysis (PCA), clusters cells that share similar
expression patterns together while accounting for potential non-
linear relationships between markers (Becher et al., 2014). With
thisapproach,we identifiedfiveclusterswithin the lineagenegative
(Lin) CD127+ population: ILC1, ILC2, ILC3, NK cell, and ‘‘non
ILCs’’ that corresponded to the phenotypes of human ILCs (Fig-
ure 1B; Spits et al., 2013). To confirm the identity of these ILC sub-
sets functionally, we performed intracellular cytokine staining,
using CD4+ T cells as a control, and, as expected, found mutually
exclusive interferon-g (IFN-g) and IL-13 production from the ILC1
and ILC2 subsets, respectively (Figure 1C). The ILC3 subset in
blood produced IL-2 and tumor necrosis factor a (TNF-a) but did
not express NKp44 (not shown) and therefore did not secrete
IL-22 (Teunissen et al., 2014). However, a high frequency of
NKp44+ ILC3s isolated from tonsil produced IL-22 (Figure 1C). InDepletion of Circulating ILCs
donor showing the hierarchical phenotype gating strategy from singlet lym-
by arrows and color-coded gates. Lineage (Lin) gate contains anti-CD3, CD4,
D45+/CD3/Lin/CD127+ that shows two-dimensional representation of high-
CD4, NKp44, CD25, CD62L, CD69, CCR6, and CD94 with gates indicating five
h marker within the five identified clusters (NK, ILC3, ILC1, ‘‘non-ILC,’’ ILC2).
4+ T cells, ILC1s, ILC2s, and ILC3s for six cytokines (IL-2, IL-13, IFN-g, TNF-a,
1 cells (CD56 gated), NK cells (CD3CD94+CD56+CD16+) ILC1, ILC2, and ILC3
ithin CD4+ T cell, ILC2, and ILC3 sorted populations from blood of nine HIV-
inette et al., 2015).
etectable plasma virus (VL < 50) (n = 16), and HIV-1-infected individuals with
ted (n = 122), HIV-1-infected with undetectable plasma virus (VL < 50) (n = 14),
es by Dunn’s test for multiple comparisons.
according to automatic (unbiased) cluster designation for accumulated data
cluster named by its unique number inside gates.
), corresponding to the tSNE plots in (H), to the overall LinCD127+ population
cted (n = 18) andHIV-1-infected (n = 21) individuals. p values by Student’s t test






Figure 2. All ILC Populations Are Depleted during Early Acute HIV-1 Infection
(A) Data from the acutelyHIV-1-infected subject (PID 0398-271) followed longitudinally over 10 timepoints fromday 1 to day 249 from the day of first HIV+ RNA test,
with ILC1s, ILC2s, and ILC3s shown as a percentage of the total CD45+ lymphocytes (left y axis, colored line) and the plasma VLs shown as HIV+ RNA copies/ml
plasma (right y axis, black line).
(legend continued on next page)
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addition, ILC subsets expressed the transcription factors T-bet,
GATA-3, and RORgt in the expected patterns for the ILC1, ILC2,
and ILC3 subsets, respectively, and relative to controls (conven-
tional NK [T-bet] andCD4-Th1 [T-bet] andTh2 [GATA-3] cells) (Fig-
ure1D;Spitsetal., 2013).Finally,weperformedRNAsequencingof
sorted ILCs andCD4+ T cells from the bloodof nine healthy donors
and found that the ILC populations displayed a distinct ILC tran-
scriptional signature compared to sample-matched CD4+ T cells
(Figure 1E; Tables S1, S2, and S3). The ILC subsets themselves
were closely related but transcriptionally distinct (Tables S1, S2,
and S3), typified by expression of canonical ILC lineage genes,
such as CD117 (cKit; ILC3), IL1R (ILC3), and KLRG1 (ILC2) (Fig-
ure S1B). Together, these data confirm the precise identification
of the main human ILC subsets described.
Next, we compared the absolute number of blood ILCs in a total
of 223 samples from HIV-1-uninfected, ART-naive viremic (HIV-1
RNA > 50 copies/ml plasma), and aviremic (<50 copies/ml)
individuals with chronic HIV-1 infection (Figure 1F). In viremic sub-
jects, we observed depletion of all three ILC populations (p <
0.0001). However, ILC1s and ILC2s, but not ILC3s (p = 0.009),
were preserved in aviremic subjects (Figure 1F). ILC frequencies
expressed as percentage of total CD45+ lymphocytes confirmed
their depletion during chronic HIV-1 (Figure 1G) and showed
that changes in frequency of other hematopoietic subsets did
not impact ILC measurements during chronic infection. In addi-
tion, we observed a significant negative correlation between
HIV-1 RNA VL setpoint and ILC frequency (p = 0.07 to 0.007,
R = 0.18 to 0.32) (Figures S2A and S2B), similar to the well-
described correlation between VL and absolute CD4+ T cell
counts (p < 0.001,R=0.47) (FigureS2C). Thus, ILCsare severely
depleted in chronic viremic infection with a direct negative corre-
lation to VL setpoint.
To examine shifts in ILC subsets driven by chronic HIV-1
infection, we used the tSNE algorithm (Becher et al., 2014) to
obtain an unbiased analysis of ILC distribution. By gating on
LinCD127+, we identified 38 distinct clusters with shared sur-
face marker expression characteristics (Figure 1H). Ten of these
clusters were significantly enriched or depleted in HIV-1-in-
fected subjects (Figure 1I), predominantly from within the ILC2
and ILC3 populations. Of these, cluster 9 (ILC2) and cluster 20
(ILC3) remained significant after controlling for multiple compar-
isons (p = 4.5 3 105 and p = 1.7 3 1011), suggesting that the
circulating ILCs that remained during chronic HIV infection were
phenotypically altered.
ILCs Are Depleted during Early Acute HIV-1 Infection
To further investigate the dynamics of ILC depletion, we turned
to a unique acute HIV-1 infection cohort (Ndhlovu et al., 2015).
Women in this cohort were tested for the presence of HIV-1 nu-
cleic acid in plasma twice a week, and therefore HIV-1 infections(B) Data as shown in (A), but for the entire cohort (n = 7).
(C) Data as shown in (B), but cumulative data presented as mean values for the
(D) Percentage ILC1s, ILC2s, and ILC3s of total CD45+ lymphocytes shown for we
uninfected subjects (n = 116).
(E) ILC frequencies expressed as absolute ILC counts shown for week 0 and we
subjects (n = 116).
(F) Data from the acutely HIV-1-infected subject (PID 0398-271) as shown in (A)
p values by Dunn’s test for multiple comparisons. All samples are from ‘‘FRESHwere identified within a maximum of 4 days from their last nega-
tive test and approximately 5–14 days after transmission, corre-
sponding to Feibig stage I (McMichael et al., 2010). We tracked
ILC1s, ILC2s, and ILC3s in seven individuals throughout the
course of peak viremia and into chronic infection (Figure 2). We
found normal ILC frequencies at the first time points that were
sampled before peak viremia but observed a rapid ILC depletion
that coincided with the peak VL (days 7–14) (Figures 2B and 2C)
and persisted without rebound into chronic infection (p < 0.016)
(Figure 2D). This observation remained significant when we
analyzed the absolute ILC counts (Figures 2E and S3A–S3C),
demonstrating that ILC depletion is not a result of changes in
the frequency of other subsets during this disease phase. In
contrast, and as expected, the characteristic early nadir of abso-
lute CD4+ T cell count, temporally associated with peak viremia,
rebounded rapidly, although to suboptimal levels (Figure 2F).
Thus, these data show that the ILC depletion observed during
chronic viremic infection occurred very early in the acute phase
of infection and that, unlike CD4+ T cells, ILCs failed to recover
after the resolution of acute viremia to setpoint VL.
Early Depletion of ILCs Coincides with Spikes in
Epithelial Gut Breakdown
ILCs are required tomaintain an effective gut barrier and to regu-
late the immune response to commensal microbiota (Sonnen-
berg et al., 2012). We therefore next sought to define the kinetics
of ILC decline in early acute HIV-1 infection in relation to the
damage to gut-associated lymphoid tissue that occurs during
primary infection in non-human primates (Veazey et al., 1998).
Changes to gut integrity during acute HIV-1 infection were as-
sessed indirectly by measuring the levels of intestinal fatty
acid binding protein 1 (I-FABP), a plasma marker previously
associated with gut barrier breakdown (Hunt et al., 2014). In
one subject (PID 0398-271), we found a peak in I-FABP levels
1 week after ILC depletion and 2 weeks after HIV-1 plasma
RNA detection (Figure S4A). When we compared the relative
levels of I-FABP for the entire cohort, we consistently found
maximum levels occurring 2 weeks after HIV-1 RNA detection
that coincided with ILC depletion (Figure S4B). Although
I-FABP levels return to baseline once VL reaches setpoint, the
association between ILC levels and I-FABP was significant at
2 and 3 weeks after HIV-1 detection (p < 0.008) (Figure S4C),
corresponding to 1week after peak viral replication (Figure S4D).
These data are consistent with the hypothesis that massive viral
replication during acute infection leads to profound damage to
the gut epithelial barrier and precipitates the well-described as-
sociation between microbial translocation, immune activation,
and disease progression. ILCs are central to gut epithelial repair,
so the 4-fold increase in I-FABP levels and coincident loss of
ILCs from circulation suggests a possible link, although thisentire cohort (n = 7) with error bars showing SEM.
ek 0 and week 6 after day of first HIV-1-positive test and compared to the HIV-
ek 6 after day of first HIV-1-positive test and compared to the HIV-uninfected
but for absolute CD4+ T cell counts (pink line, right y axis).
’’ cohort (Ndhlovu et al., 2015). See also Figures S2–S4.




Figure 3. ILCs Are Not Reconstituted after Successful Treatment Initiated in Chronic Infection
Twenty-four individuals were tested every 3 months for the presence of early detectable HIV-1-specific p24 antibodies and followed over 9 years with average
treatment initiation starting at median values of 213 weeks after infection and sampled again 2 years later.
(A) Median HIV-1 RNA copies/ml plasma before and after treatment.
(B) Absolute CD4+ T cell counts.
(C) Percentage of HLA-DR+CD38+ expression gated on CD4+ T cells and CD8+ T cells before and after ART treatment.
(D) Absolute ILC counts comparing HIV-1-uninfected individuals (n = 81) to unmatched HIV-1-infected individuals (n = 22) with successful viral suppression after
2 years of treatment.
(E) Absolute ILC1, ILC2, and ILC3 counts from matched HIV-1-infected individuals before and after ART start (n = 22) with horizontal dotted line representing
median absolute ILC counts for HIV-1-uninfected individuals.
(F) ILC frequencies expressed as percent of CD45+ lymphocytes comparing HIV-1-uninfected individuals (n = 84) to unmatched HIV-1-infected individuals with
successful viral suppression after 2 years of treatment (n = 22).
(G) Data as in (E) but expressed as percent ILCs of total CD45+ lymphocytes.
p values by the Wilcoxon matched-paired signed rank test, Mann-Whitney U test and with correlation coefficients shown as spearman rank r and p values.might be circumstantial and additional data are required to test
this correlation.
ILC Depletion Is Irreversible despite Successful
Suppression of Viremia by Antiretroviral Treatment in
Chronic Infection
Wenext sought to investigate the relationship between ILC deple-
tion and immune reconstitution after ART initiation. In a longitudi-
nal treatment cohort (Abdool Karim et al., 2010), wemeasured ILC
frequencies in chronically infected individuals at the last time
point before ART initiation (median 213 weeks after infection)
and 2 years into successful treatment (median 308 weeks after396 Immunity 44, 391–405, February 16, 2016 ª2016 Elsevier Inc.infection) (Figures 3A and 3B), as indicated by partial CD4+
T cell reconstitution (Figure 3B) and reduced immune activation
(Figure 3C). Unexpectedly, all three ILC populations failed to re-
turn to normal frequencies, and they remained significantly lower
than in uninfected individuals despite undetectable VLs (p < 0.02)
(Figures 3D–3G). Only blood ILC3s significantly rebounded with
ART (p < 0.0001), but never to the frequencies observed in unin-
fected individuals (median 70 versus 430 ILC3s). There was no
correlation between the recovery of ILCs and CD4+ T cells in
the same subjects (p > 0.7) (data not shown). Thus, the ILC deple-
tion observed during both acute and chronic HIV-1 infection was




Figure 4. ILCs Are Preserved by Treatment Initiation during Early Acute HIV-1 Infection
(A) Data from one acute infected subject (FRESH cohort) that was treated 1 day after detection of HIV-1 RNA in plasma (VL = 2,900) as indicated by the black arrow
and with ILC frequency shown as percent of CD45 lymphocytes tracked throughout 400 days after HIV-1 infection (left y axis) and with HIV-1 RNA copies/ml
plasma (right y axis). ILC1, orange; ILC2, red; ILC3, blue; viral load indicated by black lines.
(B) Longitudinal data from seven acutely HIV-1-infected subjects initiated on ART within 1 day of plasma HIV-1 detection and shown as percent ILC of CD45
lymphocytes throughout acute infection.
(C) Longitudinal mean values comparing seven acutely infected individuals initiated on ART 1 day after HIV RNA detection (colored lines) to seven acutely infected
individuals not receiving ART (gray lines) throughout 11 weeks after HIV detection with error bars representing SEM.
(D) ILC1, ILC2, and ILC3 frequencies for six acutely infected individuals receiving ART by day 1 of HIV detection (ART+ individuals at >6 weeks after HIV detection)
compared to nine treatment-naive acutely infected individuals from the same cohort 6 weeks into infection (no ART [6w]).
p values by Dunn’s test for multiple comparisons.ILC Depletion Is Prevented by Antiretroviral Treatment
Initiated during Early Acute HIV-1 Infection
To investigate the potential capacity of ART initiated in early infec-
tion to reverse the negative impact ofHIV-1 oncirculating ILCs,we
analyzed a unique subset of individuals inwhomARTwas initiated
at the earliest possible time point: on the first day of HIV-1 RNA
detection and within 5–14 days of HIV-1 transmission. From one
subject (PID 0444-312), we observed reduced peak viremia, pre-
served CD4+ T cells (871 before versus 745 cells/ml 4 weeks after
infection), and no depletion of blood ILCs (Figure 4A). The preser-
vation of ILCs relative to untreated subjects was consistent in all
seven individuals receiving ART during early acute infection (Fig-
ure 4B) in contrast to acute infected individuals that did not receivetreatment (Figure 4C). ILC frequencies in these subjects fluctuated
to some extent during the course of acute infection but no clear
patterns emerged. Whether this represents heterogeneity in the
response of ILCs in these individuals to their ART or to natural vari-
ation is unclear. However, at >6 weeks into infection, all three ILC
subsets were present at significantly higher frequencies than in
untreated subjects (p < 0.018) (Figure 4D). Thus, ILC depletion
during HIV-1 infection can be prevented by early ART.
ILC Depletion Associated with Signatures of Activation
and Fas Upregulation
ILCs are unlikely to be directly infected byHIV-1 because they do
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infect ILCs with HIV-1 using high titers of X4 and R5 virus (data
not shown). In order to investigate alternative mechanisms of
ILC depletion, we first measured the anti-apoptotic factor Bcl-
2 and activated caspase-3, which are both involved in apoptosis.
Although we were able to increase intensities of caspase-3 in all
ILC subsets by incubation with the pro-apoptotic molecule
camptothecin, we did not detect any significant changes in ab-
solute (Figure 5A) or relative (Figure 5B) intensity of Bcl-2 or cas-
pase-3 expression when comparing ILCs from HIV-1-uninfected
and chronic infected subjects. As expected (Petrovas et al.,
2004), we did detect elevated signatures of apoptosis in CD8+
T cells from chronically infected individuals using this assay
(data not shown).
We next examined the activation status of the remaining circu-
lating ILCs after HIV-1 infection, because HIV-1-induced immune
activation is implicated in CD4+ T cell depletion (Brenchley et al.,
2004). We found a significant increased surface expression of
the lymphocyte activation marker CD69 on ILC2s and ILC3s
(p < 0.0001) (Figure 5C) and on T cells (data not shown) in HIV-
1-positive subjects, demonstrating activation of ILCs in response
to infection. However, when we measured CD38, a marker of
general immune activation on T cells, we found low expression
levels on ILC1s, ILC2s, and ILC3s compared to CD4+ and CD8+
T cells, with no correlation to ILC frequencies inHIV-1-infected in-
dividuals (data not shown). In addition, we found no difference in
CD38 expression on ILC1s, ILC2s, and ILC3s comparing infected
and uninfected individuals in contrast to significant differences
observed for both CD4+ and CD8+ T cells (p < 0.01) (data not
shown), suggesting that different activation markers exist for
ILCs and T cells in HIV-1 infection. We observed significant upre-
gulation of themucosal tissue homing receptors a4b7, but only in
the ILC3 subset (Figure S5A) and not in their T cell counterparts or
in ILC1 and ILC2 subsets (data not shown).
Plasma IL-7 is known to be elevated in chronic HIV-1 infection
(Hodge et al., 2011) and it is the ligand for CD127, a receptor that
is expressed on all ILC subsets and is critical for their generation
and maintenance (Spencer et al., 2014). Therefore, we next
measured plasma levels of IL-7 by ELISA in matched samples
and found a weak positive associations with the frequency of
ILC1 and ILC2 and plasma IL-7 levels in HIV-1-infected individ-
uals, but no association with ILC3s (Figure S5B). These data sug-
gest that IL-7 does not play a role in persistent ILC depletion in
chronic HIV-1 infection.
A recent study suggests that cell death protein Fas-FasL inter-
actions are involved in ILC3 apoptosis in a humanized mouseFigure 5. ILCs from Peripheral Blood of Chronic HIV-1-Infected Individ
regulation of Fas
(A) Activated caspase-3measured bymedian fluorescence intensity (MFI) after log
ILC3 with cumulative data from MFI values for caspase-3 comparing 20 HIV-neg
(B) One representative example of percentage Bcl-2- and caspase-3-negative ILC
data shown on the right as the percentage of Bcl-2/casp-3 cells of ILC1, ILC2
(C) MFI expression for CD69 on ILC1s, ILC2s, and ILC3s comparing HIV-negativ
(D) Fas (CD95) expression on ILC1, ILC2, and ILC3 gated cells overlayed by HIV-
infected subjects (right).
(E) Plasma IP-10mean levels (left y axis) shown for 14 acutely infected treatment-n
as day7) followed 30 days into infection (left), and with four subjects treated 1 da
on the right y axis.
(F) Same as for (E) but with data for IFN-a2.
Error bars represent SEM values. p values by Mann-Whitney U test and paired tmodel of HIV-1 (Zhang et al., 2015). Therefore, we measured
the relative intensity of CD95 (Fas) expression in chronic HIV-1
and found significant upregulation on ILC2 and ILC3 subsets
measured by percent CD95 expression (Figure 5D) and for the
ILC1 subset by relative MFI (p = 0.004) (data not shown). The
Fas-mediated apoptosis reported by Zhang et al. (2015) was
driven by IFN-a, and we therefore looked to see whether the
ILC depletion observed in our acute HIV-1 cohort correlated
with plasma quantities of this cytokine, reported to be induced
in this early phase of infection (Stacey et al., 2009). Plasma con-
centrations of IFN-a and the IFN-induced protein IP-10 were
measured in samples from2 to 12weeks before infection (plotted
as day 7) followed by 3, 7, 14, and 30 days after HIV-1 RNA
detection. IP-10 was induced by primary viraemia (66%), con-
firming immune activation and the existence of a strong IFN
signature associated with acute infection (p = 0.038) (Figure 5E).
In addition, we observed a modest increase (11%) in IFN-a over
baseline prior to peak viremia (p = 0.077) (Figure 5F). In the limited
samples available (n = 4), we found that IP-10 concentrations
were greatly reduced by immediate ART, consistent with a blunt-
ed IFN response, but the impact on IFN-awas not apparent (Fig-
ures 5E and 5F). These data are consistent with the hypothesis
that ILC depletion is driven by immune activation during acute
viraemia and prevented by early treatment, although the role of
IFN-a specifically is not clear.
RNA-Seq Analysis Reveals Downregulation of Genes
Associated with Cell Viability and Proliferation in ILCs
Immediately after HIV-1 Infection
To gain a deeper understanding of ILC depletion in HIV-1 infec-
tion, we performed bulk RNA-seq on samples from early acute
infection. RNA-seq is a sensitive and powerful method for deter-
mining changes in cell populations and behaviors (Rapaport
et al., 2013). mRNA from CD4+ T cells, ILC2s, and ILC3s isolated
at various time points were sequenced from two untreated pa-
tients and two patients who started ART immediately after viral
RNA detection. Transcriptional comparisons were made be-
tween both HIV detection and peak viremia and between peak
viremia and 6 weeks after detection for each patient in order to
generate lists of significantly differentially expressed genes (Fig-
ures 6A and S6A).
First, we compared viral detection and peak viremia to under-
stand transcriptional changes in response to the antigenemia
and cytokine response associated with this phase (McMichael
et al., 2010). Both ILC2s and ILC3s in untreated patients showeduals Are Not Apoptotic but Display an Activated Phenotype and Up-
fold titration of camptothecin at 0, 8, 80, and 800 mMshown for ILC1, ILC2, and
ative and 18 chronic HIV-positive individuals for ILC1, ILC2, and ILC3 subsets.
1, ILC2, ILC3, and NK (CD3CD56+CD94+CD16+) cell subsets with cumulative
, and ILC3 subsets.
e (n = 18) and chronic HIV-positive (n = 21) subjects.
1 uninfected (gray) and HIV-1 infected (color) comparing 20 uninfected and 20
aive subjects sampled before infection (7–60 days prior to HIV detection plotted
y after HIV-1 detection (right) and with plasma HIV RNA copies/ml levels shown
test. See also Figure S5.
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Figure 6. ILCs Show Upregulation of Genes Associated with Apoptosis and Cell Death in Early Acute HIV-1 Infection
RNA-seq was performed on samples from two untreated and two early ART-treated subjects (FRESH cohort) during the course of early acute HIV infection.
(A) Sampling points and associated VLs for each patient. NB: patient 0444-312 did not have a sample collected prior to peak VL.
(B) Heat map of activation z-scores for functionally enriched gene sets differentially expressed between initial viral detection and peak viremia.
(C) Similar plot comparing enrichments between peak viremia and approximately 6 weeks after detection. z-score was calculated using log fold change in
expression values (see Experimental Procedures).
See also Figure S6.statistically significant (p < 0.01) downregulation of genes asso-
ciated with cell proliferation and viability and upregulation of
those linked to apoptosis and cell death (Figures 6B and S6B,
Table S4). These changes were less apparent in an early acute
ART-treated patient (PID 0629-453), demonstrating a mitigated
response to HIV infection. In addition, several key upstream im-
mune regulators were found to change in ILC2s and ILC3s imme-
diately after infection (Figure S6D). Although ILCs lack T cell
receptor expression at the protein level, there were significant
changes in genes associated with CD3, also reported in tran-
scriptional profiling of ILCs in murine models (Robinette et al.,
2015). However, we found no evidence of TCR gene modules
and the role of these genes in ILCs is unclear.
We also compared transcriptional profiles of ILCs at peak
viremia and approximately 6 weeks after infection to probe the
state of the ILCs that survive acute infection. In contrast to early
changes, we found that ILC2s from untreated patients displayed
upregulated cell proliferation and cell viability and downregu-
lated cell death and apoptosis (Figures 6C and S6C, Table S5).
This was consistent with our flow cytometry data showing that
ILCs persisting in chronic infection show no evidence of
increased apoptosis or cell death. Additionally, although pheno-
typically skewed (see Figures 1H and 1I), the remaining ILCs
show signs of typical cellular function and immune response
(Figure S6E). The early ART-treated patients, on the other
hand, show mixed responses after peak viremia. Thus, ILC2s400 Immunity 44, 391–405, February 16, 2016 ª2016 Elsevier Inc.and ILC3s, in the absence of early antiretroviral treatment, un-
dergo cell death by apoptosis during peak viremia.
Tonsil- and Gut-Resident ILCs Are Not Enriched or
Depleted in Chronic HIV-1 Infection
Current studies of the involvement of ILCs in disease have
focused primarily on their effector function in lymphoid and
non-lymphoid tissue such as lung, skin, and intestine (McKenzie
et al., 2014). Therefore, to investigate how changes in circulating
ILCs relate to lymphoid-tissue-resident cells, we next turned to
tissue samples from HIV-1-infected and uninfected subjects.
We first examined surgically removed tonsils, lymphoid organs
that support HIV-1 replication and undergo profound tissue
remodeling during progressive disease (Doitsh et al., 2014;
Sanchez et al., 2015). We identified tissue-resident ILCs and
confirmed these subsets by transcription factor staining in com-
parison to NK and CD4+ Th2 cells (Figure 7A). We found higher
frequencies of ILC1s and ILC3s, but not ILC2s, compared to
the blood (Figure S7A), with a distinct CD69+ and CD62L
phenotype (Figure 7B) that is characteristic of tissue-resident T
lymphocytes. No significant depletion of CD4+ T cells from the
HIV-1-infected tonsils, known to be directly infected by the virus,
was observed (Figure 7C; Doitsh et al., 2014). Interestingly, no
significant effect of HIV-1 on ILC frequency, subtype, or pheno-
type in tonsil tissues was observed (Figures 7D and 7E), nor any







(legend on next page)
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(data not shown), that might explain their loss from circulation.
We next examined ILC frequencies in the gut mucosa, which is
a major site of HIV-1 replication and CD4+ T cell depletion (Mat-
tapallil et al., 2005) and where ILC3s play a crucial role in homeo-
stasis and barrier function. Using gut biopsies from subjects un-
dergoing colonoscopy, we identified a distinct lineage-negative
CD127+ ILC population that was dominated by cKit-positive
ILC3s expressing CD56, NKp44, CCR6, CD69, and transcription
factors RORgt, Helios, and AHR (Figure 7F). In 46 subjects, we
found increased levels of ILC1 and ILC3, but not ILC2, compared
to tonsil and blood (p < 0.0001) (Figure 7G). However, we
observed no differences in gut-resident ILC frequencies be-
tween HIV-1-infected (n = 9) and uninfected (n = 37) individuals,
nor dowe detect any difference in NKp44 andCD56 ILC3 pheno-
type (Figure 7G). Together these data provide no evidence that
ILCs are either recruited to or depleted from lymph nodes or
the gut mucosal barrier.
Finally, to assess the impact of HIV-1 on ILC function, we
measured cytokine production in tonsil ILCs from infected and
uninfected individuals, stimulated non-specifically with PMA
and ionomycin. Cytokine production in these cells was restricted
to NKp44+ ILC3s (Figures 7H and S7B; p < 0.0001) and was
dominated by IL-2, TNF-a, and GM-CSF and, to a lesser extent,
IL-22. No IFN-g or IL-13 was detected from NKp44+RORgt+
ILC3s (data not shown). Although a consistent trend was
observed for decreased cytokine production in tonsil-resident
ILC3s from HIV-1-infected individuals, these differences were
not significant in the sample size obtained here. Taken together,
ILC frequencies in tonsil and gut tissue from HIV-infected sub-
jects did not support ILC redistribution from circulation.
DISCUSSION
The role of ILCs during chronic viral infection in humans remains
unclear (Diefenbach, 2013), despite compelling evidence high-
lighting the importance of ILCs in immune regulation and
mucosal barrier maintenance (Sonnenberg et al., 2012; Tait
Wojno and Artis, 2012). Here, we report a rapid and irreversible
depletion of blood ILCs during acute HIV-1 infection that persists
in chronic infection in proportion to VL. During the chronic phase,
ILC depletion is associated with altered subset composition and
increased expression of activation (CD69) and tissue homingFigure 7. Magnitude and Phenotype of Tissue-Resident ILCs Identified
(A) Gating of live CD45+CD3 ILC1s (LinCD127+CD161+CRTH2CD117
CRTH2CD117+CD56/+), NK cells (CD3CD94+CD56+), and CD4+ Th2 cells (CD
stained for T-bet, Eomes, GATA-3, Helios, AHR, and RORgt transcription factors
(B) Median fluorescence intensity (MFI) of CD69 and CD62L expression on ILC1, I
subsets in tonsils (NKp44 not expressed in blood cells).
(C) Frequency of CD4+ T cells shown as percent of CD45+ cells within tonsil cells
(D) Comparing ILC1, ILC2, and ILC3 subsets expressed as percent of CD45+ lym
(E) ILC3 phenotype distribution of CD56- and NKp44-positive and -negative subse
data for a total of 21 subjects.
(F) Gut-tissue-resident live CD45+CD3CD4 lymphocytes gated as in (A) with ILC
for RORgt, Helios, and AHR transcription factors for gut Lin+, CD4+ T, and NK ce
(G) Cumulative data for ILC1, ILC2, and ILC3 frequencies expressed as percent of
frequencies shown for 39 HIV-1-uninfected and 9HIV-infected subjects (middle) a
and -infected subjects (right).
(H and I) Intracellular cytokine staining after media or PMA/ionomycin stimulation
gated cells (H) and with cumulative data shown in (I) obtained from HIV-1-infecte
p values by the Wilcoxon matched-paired signed rank test and Mann-Whitney U
402 Immunity 44, 391–405, February 16, 2016 ª2016 Elsevier Inc.(a4b7) markers and the Fas death receptor (CD95). Upregulation
of FAS makes ILC3s more susceptible to anti-CD95 antibody-
induced apoptosis in vitro (Zhang et al., 2015); however, we
detect no apoptotic ILCs ex vivo in chronic human HIV-1 infec-
tion measured either by caspase 3 activation or loss of bcl-2.
In contrast, in early acute infection, we find that ILCs upregulate
genes associated with cell death and apoptosis, potentially ex-
plaining their disappearance in the absence of early ART. This
coincides with a strong IFN response induced by peak viral repli-
cation, demonstrated by the rapid elevation in plasma IP-10 and
to a lesser extent IFN-a. We find no evidence of enrichment of
tissue-resident ILCs in either tonsil or gut samples, suggesting
that ILC depletion from circulation is explained by apoptosis
rather than tissue redistribution.
Despite the correlation between VL and ILC levels in chronic
infection, removal of viral burden and reduction of immune acti-
vation during this phase with fully suppressive ART does not
restore circulating ILC populations. There is a partial rebound
of ILC3s, but they remain well below the levels found in healthy
donors. This suggests that sustained viremia leads to a funda-
mental impairment of the ILC arm of the immune system, which
could have far-reaching immunological consequences (Marche-
tti et al., 2013). The role of acute viremia in ILC depletion is sup-
ported by data from patients in whom ART was initiated prior to
peak viremia. In these individuals we observe no sustained
depletion of ILCs and, in contrast to untreated individuals or
those treated later, ILCs remain at the levels observed in unin-
fected individuals. This is associated with an absence of the
transcriptional signature of apoptosis and the strong plasma
IP-10 response observed in the untreated individuals. What
role this early IFN response has in ILC depletion is not clear
from our data, although IFN-a in particular has been implicated
in ILC3 depletion in the humanized mouse model (Zhang et al.,
2015). Importantly, depletion of ILCs from blood is not a general
acute phase response to infection; filarial infection in humans is
associated with expansion of blood ILCs (Boyd et al., 2014),
suggesting the specific relevance of this phenomena to HIV-1.
Indeed, more than 90% of individuals sampled from the same
populations investigated here were infected with CMV and
EBV (unpublished data), yet displayed normal blood ILC levels
compared to individuals from areas without endemic viral infec-
tions (Munneke et al., 2014). In addition, direct infection of ILCsusing Transcription Factors within Tonsil and Gut Tissue
CD56), ILC2s (LinCD127+CD161+CRTH2+), ILC3s (LinCD127+CD161+-
3+CD4+CRTH2+) and overlayed for CD69, CD56, and NKp44 expression and
.
LC2, and ILC3 subsets in tonsil- and blood-resident T cells with NKp44+/ ILC3
obtained from 12 HIV-uninfected and 10 HIV-infected subjects.
phocytes in HIV-infected (n = 12) and uninfected (n = 12) individuals.
ts with FACS plot showing one representative example and pie charts showing
3s overlayed on Lin+ (CD45+CD3Lin+) shown for CCR6 and CD69 and shown
lls and ILC3s.
CD45+ lymphocytes from gut, tonsil, and blood (left) with ILC1, ILC2, and ILC3
nd comparing ILC3 NKp44/CD56 phenotype expression fromHIV-1-uninfected
for 5 hr shown for IL-2, TNF-a, IL-22, and GM-CSF production in NKp44+ ILC3
d (n = 9) and uninfected (n = 14) individuals.
test with horizontal bars representing median values. See also Figure S7.
by HIV-1 is highly unlikely because they lack viral entry receptors
consistent with resistance to high titered in vitro infection of
either X5 or R4 virus.
Those ILCs that do survive peak viremia and persist in chronic
infection show no evidence of apoptosis by protein expression
(Bcl-2 and active caspase-3) and exhibit comparatively downre-
gulated apoptosis and cell death transcription signatures by
RNA-seq. In fact, genes associated with viral infection and im-
mune response are upregulated in these populations, consistent
with the measured increase in CD69 expression. Whether a
certain subset of ILCs never initiates apoptosis in early acute
infection or a population is consistently renewed at lower levels
in the blood during chronic infection remains unclear.
In addition to apoptosis during acute infection, a potential
mechanism for the depletion of circulating ILCs is that they
home to major sites of HIV-1 replication and tissue damage.
The fact that we detect no significant increase in ILCs within
tonsil or gut tissue might be due to sensitivity. However, signifi-
cant increases in ILC subsets are detectable in the livers of
fibrotic mice (McHedlidze et al., 2013) and skin of human psori-
asis sufferers (Teunissen et al., 2014). Furthermore, significant
enrichment of NKp44+ lineage-negative cells, which probably
represent the ILC3 NKp44+ subset, are observed in the tonsils
of SIV-infected macaques (Reeves et al., 2011). Subsequent
studies observed depletion of the ILC3 NKp44+ subset from
theGALT andmesenteric lymph nodes of acutely and chronically
SIV-infected macaques (Li et al., 2014; Xu et al., 2015). Why an
enrichment of NKp44+ ILCs occurs in the tonsils of SIV-chal-
lengedmonkeys and not in naturally infected human subjects re-
mains unclear, but these data imply that either enrichment or
depletion of ILCs in the context of retroviral infection would be
possible to detect.
The fact that Li et al. (2014) observed a depletion of an ILC3-
like subset from the GALT of acutely SIV-infected macaques is
consistent with the depletion of circulating ILC3s we observe in
acute HIV-1 infection and concomitant spike in I-FABP levels.
The limited recovery of blood ILC3s observed after successful
drug treatment suggests that this subset remains impaired and
that continued immune activation might relate to the functional
inability of gut-resident ILC3s in HIV-1-infected individuals
(Zhang et al., 2015) to restore gut barrier integrity and preventmi-
crobial translocation (Brenchley et al., 2004). Whether ILCs play
a direct role in the HIV-1 pathology is difficult to study in human
samples and therefore animal studies are warranted to elucidate
the mechanistic details relating to the direct consequence of ILC
depletion in HIV/SIV pathology (Reeves et al., 2011; Zhang et al.,
2015). However, we believe that ILCs are likely to play an impor-
tant role in HIV-1 pathology given the existence of an IL-22-pro-
ducing NKp44+ ILC3 subset that is required to both maintain the
gut mucosa and limit the response to gut microbial contents
(Cella et al., 2009; Sonnenberg et al., 2012). Irreversibly depleted
ILC3s by HIV-1 infection would suggest a clear mechanism
behind the continued immune activation observed even in indi-
viduals with successful long-term viral suppression by ART
(Sanchez et al., 2015; Zeng et al., 2012), which is the strongest
predictor for the onset of AIDS (Hunt et al., 2014).
In summary, we demonstrated that the persistent and irrevers-
ible ILC depletion that occurs immediately after HIV-1 acquisition
correlates with disease stage and is not restored by long-termfully suppressive ART, but can be blocked by early treatment.
This provides a potential mechanistic link between HIV-1 infec-
tion, lymphoid tissue breakdown, and persistent immune
dysfunction that merits further exploration and suggests the
importance of early ART administration inmaintaining normal im-
mune system composition and functionality.
EXPERIMENTAL PROCEDURES
Subjects
We used samples from a total of 122 HIV-1-uninfected subjects and 137 HIV-
1-infected subjects. All participants were women with sub-Saharan Zulu/
Xhosa ancestry from four independently collected cohorts within or in the
greater area of Durban, KwaZulu-Natal, South Africa. All subjects provided
informed consent and each study was approved by the respective institutional
review boards including the Biomedical Research Ethics Committee of the
University of KwaZulu-Natal for all the studies. See Supplemental Experi-
mental Procedures for further information.
Clinical Parameters
VLs were obtained with the Roche Amplicor 1.5 assay (iThimba and CAP-
RISA002 cohorts) or the BioMerieux Nuclisens v2.0 (FRESH and GATEWAY
cohorts) at Global Clinical and Viral Laboratories, Durban, South Africa.
CD4+ T cell counts and total lymphocyte countswere determined as previously
described (Abdool Karim et al., 2010).
Flow Cytometry
We used different antibody panels for phenotype and transcription factor
staining. See Supplemental Experimental Procedures for specific antibodies
used throughout the study.
All samples were surface stained at room temperature for minimum 20 min
and intracellularly stained at room temperature for at least 20 min. All samples
were fixed in 2% paraformaldehyde before acquisition on a 4 laser, 17 param-
eter BD Fortessa flow cytometer within 24 hr of staining. Data were analyzed
with FlowJo v.9.7.2 (TreeStar).
ELISA
Intestinal Fatty Acid Binding Protein (I-FABP) was measured using the ELISA
kit human FABP2 DuoSet and R&D Systems and plasma IL-7 levels were
measured using the recombinant human IL-7 kit from R&D Systems (cat#
207-iL). IFN-a and IP-10 were measured with the Milliplex kit (Millipore) and
completed according to the manufacturer’s protocol.
tSNE Analysis of Flow Cytometry Data
Unbiased representations of multi-parameter flow cytometry data were gener-
ated using the t-distributed stochastic neighbor embedding (tSNE) algorithm
(van der Maaten and Hinton, 2008). tSNE is a non-linear dimensionality reduc-
tion method that optimally places cells with similar expression levels near to
each other and cells with dissimilar expression levels further apart. See Sup-
plemental Experimental Procedures for how tSNE analyses were executed.
RNA-Seq
CD4+ T cells, ILC2s, and ILC3s (100,000–50 cells) were sorted from PBMCs as
described above into 300 ml of RLT Lysis Buffer (QIAGEN) supplemented with
1% v/v 2-mercaptoethanol, briefly vortexed, spun down, and snap-frozen on
dry ice. Cellular mRNA was then isolated and processed for RNA-seq as
described previously (Trombetta et al., 2014). See Supplemental Experimental
Procedures for details.
Sequencing libraries were then prepared from WTA product using Nextera
XT (Illumina). After library construction, one final AMPure XP SPRI clean-up
(0.8 volumes) was conducted. Library concentration and size were measured
with the KAPA Library Quantification kit (KAPA Biosystems) and a TapeStation
(Agilent Technologies), respectively. Finally, samples were sequenced on a
NextSeq500 (30 bp paired-end reads) to an average depth of 5 million reads.
See Supplemental Experimental Procedures for details on gene expression
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Statistical Analyses
We used the Mann-Whitney U-test for comparison of median values between
two groups only and the Dunn’s multi comparisons test to compare median
values of more than two groups. The Wilcoxon matched-pairs signed rank
test was used for paired testing of median values before and after antiretroviral
treatment for matched samples. We used the Spearman rank correlation test
to compare correlation between two parameters and reported r-values and p
values. Statistical analyses were performed with GraphPad Prism v.6.0c
(GraphPad Software).
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The accession number for the RNA-seq data reported in this paper is GEO:
GSE77088.
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mental Experimental Procedures and can be found with this article online at
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